Skip to content
Review

ACG Clinical Guideline: Preventive Care for Patients With Cirrhosis.

Oct 2026 · American Journal of Gastroenterology · 0 citations · 153 references
Medicine

TL;DR

Recommendations for prevention of cirrhosis-specific complications, infection prevention, lifestyle factors, and non-liver-specific conditions are provided and an implementation framework of education, stakeholder engagement, and practice integration is provided to translate these recommendations into routine care.

Abstract

Cirrhosis affects more than 2 million Americans and drives substantial healthcare utilization, impaired quality of life, and mortality. Because early-stage disease carries a favorable prognosis and decompensated patients can recompensate, systematic delivery of preventive care is essential. Under the auspices of the American College of Gastroenterology Practice Parameters Committee, a writing group of hepatology experts and 2 Grading of Recommendations, Assessment, Development, and Evaluation methodologists developed PICO questions, conducted librarian-assisted searches of PubMed, Embase, and the Cochrane Library, and prioritized systematic reviews, meta-analyses, and randomized trials. The resulting guidance comprises 18 Grading of Recommendations, Assessment, Development, and Evaluation-assessed recommendations and 6 key concept statements spanning 4 domains: prevention of cirrhosis-specific complications, infection prevention, lifestyle factors, and non-liver-specific conditions. Strong recommendations include carvedilol or variceal ligation of high-risk esophageal varices, semiannual hepatocellular carcinoma surveillance, hepatitis A testing and vaccination, influenza, severe acute respiratory syndrome coronavirus 2, respiratory syncytial virus immunization, and smoking-cessation counseling. Conditional recommendations address lactulose for minimal hepatic encephalopathy, adjunctive rifaximin after hospitalization, short-course antibiotic prophylaxis for upper gastrointestinal bleeding, postdischarge behavioral therapy for alcohol use disorder, dietitian-guided nutrition, structured exercise, and bisphosphonates for osteoporosis. Most evidence was of low certainty. We provide an implementation framework of education, stakeholder engagement, and practice integration to translate these recommendations into routine care.

View source

Similar papers

Review Oct 2026

Surveillance for Hepatocellular Carcinoma in Patients at High Risk.

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and most often arises in patients with chronic liver disease and cirrhosis. Since curative treatment options are largely limited to early-stage disease, effective surveillance strategies are essential to improve outcomes. Cu...

Kathryn J. Fowler, A. Kamaya, S. Rodgers et al. · 0 citations
Review Open access Aug 2026

Liver cirrhosis in Bangladesh: a systematic review of etiology, complications and management gaps

Liver cirrhosis represents a significant and growing cause of morbidity and mortality in Bangladesh, reflecting the increasing burden of chronic liver diseases in low- and middle-income countries. This systematic review aims to evaluate the current etiological patterns of cirrhosis in Bangladesh, summarize its major co...

M. Akther, Bismoy Saha, M. Khan et al. · 0 citations
Review Open access Sep 2026

Hepatocellular carcinoma surveillance in MASLD: from cirrhosis-based screening to personalized risk stratification.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a major risk factor for hepatocellular carcinoma. Compared with viral-related liver cancer, MASLD-associated hepatocellular carcinoma occurs at older age, is often diagnosed at more advanced stages, a...

Rosanna Villani, G. Serviddio · 0 citations
Review Open access Sep 2026

Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice

Summary Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and a public health concern, with 75% of cases considered preventable. Biannual liver ultrasound, with or without serum alpha-fetoprotein, is recommended as surveillance for patients at high risk of HCC. While the rationale...

Maria Qurashi, Maria Buti, Grace Lai-Hung Wong et al. · 1 citation
Open access Aug 2026

Diagnosis, clinical assessment, and staging of hepatocellular carcinoma: a Brazilian multidisciplinary consensus

This multidisciplinary consensus provides practical, evidence-based recommendations for the diagnosis, clinical assessment, and staging of HCC, and promotes standardized diagnostic practices while reinforcing comprehensive patient evaluation and multidisciplinary management.

F. Coimbra, André Luís de Godoy, P. H. de Sousa Fernandes et al. · 0 citations
Review Open access Sep 2026

Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma

Abstract Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality and arises predominantly in cirrhotic livers, making prognosis and treatment response highly dependent on hepatic reserve and comorbidity. With multiple first-line immunotherapy and anti-VEGF based regimens, real-world decision making r...

A. Syed, M. Akce, Midhun Malla · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.